JP2018514208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514208A5 JP2018514208A5 JP2017555766A JP2017555766A JP2018514208A5 JP 2018514208 A5 JP2018514208 A5 JP 2018514208A5 JP 2017555766 A JP2017555766 A JP 2017555766A JP 2017555766 A JP2017555766 A JP 2017555766A JP 2018514208 A5 JP2018514208 A5 JP 2018514208A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid construct
- construct according
- signal
- intracellular retention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims description 67
- 108020004707 nucleic acids Proteins 0.000 claims description 55
- 102000039446 nucleic acids Human genes 0.000 claims description 55
- 230000031852 maintenance of location in cell Effects 0.000 claims description 40
- 108091005703 transmembrane proteins Proteins 0.000 claims description 29
- 102000035160 transmembrane proteins Human genes 0.000 claims description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 238000003776 cleavage reaction Methods 0.000 claims description 9
- 230000007017 scission Effects 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 230000014759 maintenance of location Effects 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 4
- 210000003712 lysosome Anatomy 0.000 claims description 4
- 230000001868 lysosomic effect Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 210000003412 trans-golgi network Anatomy 0.000 claims description 4
- 108010027410 Adenovirus E3 Proteins Proteins 0.000 claims description 2
- 241000710190 Cardiovirus Species 0.000 claims description 2
- 102100039371 ER lumen protein-retaining receptor 1 Human genes 0.000 claims description 2
- 102000004961 Furin Human genes 0.000 claims description 2
- 108090001126 Furin Proteins 0.000 claims description 2
- 101000812437 Homo sapiens ER lumen protein-retaining receptor 1 Proteins 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 241000723792 Tobacco etch virus Species 0.000 claims description 2
- 108091005906 Type I transmembrane proteins Proteins 0.000 claims description 2
- 102000003425 Tyrosinase Human genes 0.000 claims description 2
- 108060008724 Tyrosinase Proteins 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 230000012202 endocytosis Effects 0.000 claims description 2
- 210000001163 endosome Anatomy 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 238000004064 recycling Methods 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 230000002132 lysosomal effect Effects 0.000 claims 2
- 101150049689 tyrP gene Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 102000035087 single-pass transmembrane proteins Human genes 0.000 description 1
- 108091005496 single-pass transmembrane proteins Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1507104.6A GB201507104D0 (en) | 2015-04-27 | 2015-04-27 | Nucleic acid construct |
| GB1507104.6 | 2015-04-27 | ||
| PCT/GB2016/051164 WO2016174408A1 (en) | 2015-04-27 | 2016-04-26 | Nucleic acid construct |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020117039A Division JP2020171313A (ja) | 2015-04-27 | 2020-07-07 | 核酸構築物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514208A JP2018514208A (ja) | 2018-06-07 |
| JP2018514208A5 true JP2018514208A5 (enExample) | 2019-04-11 |
| JP6836515B2 JP6836515B2 (ja) | 2021-03-03 |
Family
ID=53488689
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555766A Active JP6836515B2 (ja) | 2015-04-27 | 2016-04-26 | 核酸構築物 |
| JP2020117039A Withdrawn JP2020171313A (ja) | 2015-04-27 | 2020-07-07 | 核酸構築物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020117039A Withdrawn JP2020171313A (ja) | 2015-04-27 | 2020-07-07 | 核酸構築物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11530420B2 (enExample) |
| EP (1) | EP3288968B1 (enExample) |
| JP (2) | JP6836515B2 (enExample) |
| CN (1) | CN107532176A (enExample) |
| AU (1) | AU2016254498B2 (enExample) |
| CA (1) | CA2984101A1 (enExample) |
| ES (1) | ES2847698T3 (enExample) |
| GB (1) | GB201507104D0 (enExample) |
| HK (1) | HK1244021A1 (enExample) |
| WO (1) | WO2016174408A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201609118RA (en) | 2014-05-15 | 2016-11-29 | Univ Singapore | Modified natural killer cells and uses thereof |
| GB201507108D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
| EP3325633A4 (en) * | 2015-09-04 | 2019-01-16 | Tocagen Inc. | RECOMBINANT VECTORS COMPRISING A 2A PEPTIDE |
| AU2017363278B2 (en) | 2016-11-22 | 2022-10-27 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
| JP7137896B2 (ja) * | 2017-03-24 | 2022-09-15 | レンティジェン・テクノロジー・インコーポレイテッド | 抗ｃｄ３３免疫療法によりがんを処置するための組成物および方法 |
| RU2019128544A (ru) | 2017-03-27 | 2021-04-28 | Нэшнл Юниверсити Оф Сингапур | Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров |
| CN110636851B (zh) | 2017-03-27 | 2023-11-03 | 新加坡国立大学 | 截短的nkg2d嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| US11389525B2 (en) | 2017-10-27 | 2022-07-19 | Statens Serum Institut | Polygene influenza vaccine |
| CN108359014A (zh) * | 2018-02-08 | 2018-08-03 | 四川农业大学 | 含有dhav-1 2a1-p的多肽及其介导的多蛋白共表达方法 |
| CA3089170A1 (en) | 2018-02-09 | 2019-08-15 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| GB201805918D0 (en) | 2018-04-10 | 2018-05-23 | Autolus Ltd | Cell |
| CA3110282A1 (en) * | 2018-08-24 | 2020-02-27 | Locanabio, Inc. | Fasl immunomodulatory gene therapy compositions and methods for use |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| SG11202109057XA (en) | 2019-03-05 | 2021-09-29 | Nkarta Inc | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| GB201914611D0 (en) * | 2019-10-09 | 2019-11-20 | Autolus Ltd | Engineered immune cell |
| WO2024197792A1 (en) * | 2023-03-31 | 2024-10-03 | Beijing University Of Chinese Medicine | A complex comprising a cell penetrating peptide and a copi sorting inhibitor and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998017323A1 (en) * | 1996-10-23 | 1998-04-30 | The Trustees Of The University Of Pennsylvania | Improved vaccines |
| CA2615983A1 (en) * | 2005-07-21 | 2007-02-01 | Abbott Laboratories | Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis |
| CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| JP2016502405A (ja) * | 2012-11-21 | 2016-01-28 | メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー | ボツリヌス神経毒の生物学的活性を決定するための手段及び方法 |
| CN111849912B (zh) * | 2014-02-14 | 2024-03-15 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| SG11201705914SA (en) | 2015-01-26 | 2017-08-30 | United States Mineral Prod Co | Corrosion resistant spray applied fire resistive materials |
-
2015
- 2015-04-27 GB GBGB1507104.6A patent/GB201507104D0/en not_active Ceased
-
2016
- 2016-04-26 CA CA2984101A patent/CA2984101A1/en not_active Abandoned
- 2016-04-26 JP JP2017555766A patent/JP6836515B2/ja active Active
- 2016-04-26 EP EP16720483.3A patent/EP3288968B1/en active Active
- 2016-04-26 CN CN201680024069.5A patent/CN107532176A/zh active Pending
- 2016-04-26 HK HK18103619.5A patent/HK1244021A1/zh unknown
- 2016-04-26 US US15/568,859 patent/US11530420B2/en active Active
- 2016-04-26 ES ES16720483T patent/ES2847698T3/es active Active
- 2016-04-26 WO PCT/GB2016/051164 patent/WO2016174408A1/en not_active Ceased
- 2016-04-26 AU AU2016254498A patent/AU2016254498B2/en not_active Ceased
-
2020
- 2020-07-07 JP JP2020117039A patent/JP2020171313A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514208A5 (enExample) | ||
| JP2018514209A5 (enExample) | ||
| Fujii et al. | PA tag: a versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin | |
| JP6836515B2 (ja) | 核酸構築物 | |
| ES2869971T3 (es) | Construcción de ácido nucleico | |
| JP2016533174A5 (enExample) | ||
| ZA202006432B (en) | T cell receptors | |
| WO2011039508A3 (en) | T-cell receptor | |
| JP2019521643A5 (enExample) | ||
| JP7704685B2 (ja) | 抗原結合タンパク質 | |
| Tang et al. | Molecular cloning and localization of human syntaxin 16, a member of the syntaxin family of SNARE proteins | |
| HRP20220080T1 (hr) | Poboljšane imunoglobulinske varijabilne domene koje vežu serumski albumin | |
| WO2017172981A3 (en) | Chimeric antigen receptors targeting cancer | |
| Carrington et al. | Sequence and expression of the glycosyl-phosphatidylinositol-specific phospholipase C of Trypanosoma brucei | |
| IL274547B1 (en) | Modified ligand-gated ion channels and methods of use | |
| JP2018531624A5 (enExample) | ||
| HK1215441A1 (zh) | 人血清白蛋白结合化合物及其融合蛋白 | |
| Demirel et al. | Tuning the cellular trafficking of the lysosomal peptide transporter TAPL by its N‐terminal domain | |
| Forti et al. | Identification of a novel overlapping sequential E epitope (E′) on the bovine leukaemia virus SU glycoprotein and analysis of immunological data | |
| Nogi et al. | Novel affinity tag system using structurally defined antibody‐tag interaction: application to single‐step protein purification | |
| Schwardt et al. | The negative regulator of Borna disease virus polymerase is a non-structural protein | |
| WO2009002939A3 (en) | Autophilic antibodies | |
| MX2012009942A (es) | Vector de expresion. | |
| US7994148B2 (en) | Transmembrane delivery peptide and bio-material comprising the same | |
| JP2015527074A5 (enExample) |